Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren’t giving them a good review.
Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...
Ozempic is synonymous with weight loss for many people, even as they can turn to drugs with other brand names that have been tailored to treat obesity. The blockbuster Type 2 diabetes medication ...